- Home
- AGEN vs SNT Comparison
AGEN vs SNT Comparison
Compare AGEN & SNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- SNT
- Stock Information
- Founded
- AGEN 1994
- SNT 1965
- Country
- AGEN United States
- SNT Canada
- Employees
- AGEN N/A
- SNT N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- SNT Telecommunications Equipment
- Sector
- AGEN Health Care
- SNT Telecommunications
- Exchange
- AGEN Nasdaq
- SNT Nasdaq
- Market Cap
- AGEN 38.1M
- SNT 80.4M
- IPO Year
- AGEN 2000
- SNT 1993
- Fundamental
- Price
- AGEN $1.60
- SNT $3.38
- Analyst Decision
- AGEN Buy
- SNT
- Analyst Count
- AGEN 4
- SNT 0
- Target Price
- AGEN $8.00
- SNT N/A
- AVG Volume (30 Days)
- AGEN 500.1K
- SNT 19.3K
- Earning Date
- AGEN 05-06-2025
- SNT 04-21-2025
- Dividend Yield
- AGEN N/A
- SNT N/A
- EPS Growth
- AGEN N/A
- SNT N/A
- EPS
- AGEN N/A
- SNT 0.06
- Revenue
- AGEN $103,463,000.00
- SNT $34,455,000.00
- Revenue This Year
- AGEN $4.03
- SNT N/A
- Revenue Next Year
- AGEN $5.57
- SNT N/A
- P/E Ratio
- AGEN N/A
- SNT $59.51
- Revenue Growth
- AGEN N/A
- SNT 2.04
- 52 Week Low
- AGEN $1.44
- SNT $1.08
- 52 Week High
- AGEN $19.69
- SNT $3.97
- Technical
- Relative Strength Index (RSI)
- AGEN 28.09
- SNT 47.94
- Support Level
- AGEN $1.44
- SNT $3.42
- Resistance Level
- AGEN $1.77
- SNT $3.54
- Average True Range (ATR)
- AGEN 0.14
- SNT 0.10
- MACD
- AGEN 0.03
- SNT 0.01
- Stochastic Oscillator
- AGEN 32.00
- SNT 73.61
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.